PhinC Development, a company specialized in early drug development strengthens its offer in pharmacometrics. This new PBPK service (Physiologically Based Pharmacokinetic) is powered by GastroPlus® software, acquired in partnership with Genopole®. Such efficient but expensive technology will be no longer reserved to "big pharma" but, now, to smaller biotechnology companies developing drugs.
In France, there are about 300 molecules under clinical development for therapeutic or diagnostic use. Although, a relevant number of these molecules will enter clinical development, only few will actually be available to patients. An extensive analysis of preclinical data appears as one of the primary way to limit the number of "false start" of new molecules that will never reach upper phase of development.
Better use of preliminary data is possible using predictive models from PBPK approaches. GastroPlus® software suits perfectly this approach in performing intra & inter-species simulations of absorption and distribution of compounds. Thanks to an iterative approach, a first PBPK model is built on the basis of experimental obtained at early stages. Models are then adjusted at each stage of pre-clinical development and new simulations are made by comparing the experimental results. It allows optimizing the study plan from the pre-clinical studies to first trials in Humans, saving time, limiting the number of pre-clinical experiments on animals and, finally, reducing the overall cost of development.
Bernard Orlandini, Managing Director and co-founder of PhinC Development "Thanks to our partnership with Genopole®, GastroPlus® software will finally enhance drug development in biotechs. PhinC is proud to bring pharmacometrics and drug development skills necessary to a smart use of GastroPlus®".
About PhinC Development
Founded in 2008 and located on the French bio-park of Genopole ® in Evry, PhinC Development is a service company that specializes in early stage development of drug candidates. PhinC offers two types of services. The first one is an operational support "integrated" to the R&D biotech teams allowing them to have all the tools (methodological, scientific and regulatory) to guide their development program and perform strategic and enlighten decision making. The second is the execution of statistical, PK and pharmacometrics analyses (principle of MBDD, Model Based Drug Development) to exploit the key steps of drug development, thereby saving time and money.
Visit our website at: www.phinc.fr
